Enabling people to live longer and healthier lives is fundamental to progress in global health.

R&D on the part of the innovative pharmaceutical industry helps reduce premature mortality from NCDs. It provides new treatments, supports prevention measures, and improves the quality of care.

Through partnerships and collaborations such as Access Accelerated, we drive different activities in LMICs that contribute toward a shared goal of reducing NCD deaths globally.

This spans capacity building, promoting health literacy, fostering patient empowerment, strengthening health systems in low-resource areas, and working on pricing and affordability solutions to make medicines more accessible to the global population.

Around 3,148 cancer medicines are currently being developed through the innovative pharmaceutical industry’s continued R&D.

In the past 50 years, understanding of cancer has advanced considerably, leading to new and more effective treatments.

The innovative pharmaceutical industry is dedicated to improving global cancer management based on more effective partnerships and collaborative approaches to providing access to healthcare.

For instance, it plays a key role in integrated care, where organizations partner to deliver services that best serve populations.

Where the burden of cancer and its economic impact are growing worldwide, companies work constantly to adapt R&D and models to improve access to innovative treatments.

Looking to the future, the innovative pharmaceutical industry believes that capacity to strengthen health literacy and healthcare workforce must be increased. To address existing health inequities and gaps in cancer care management, palliative care also needs to become more efficient.

As part of the Global Monitoring Framework on NCDs, World Health Organization (WHO) member states have committed to reporting cancer incidences in the 2025 mortality target.

To support this, we encourage the use of cancer registries that are designed to advance clinical research, better understand cancer trends, and develop a more targeted and efficient approach to prevention, diagnosis, and treatment.

Since the early days of the Millennium Development Goals (MDGs) – replaced by the SDGs in 2015 – the innovative pharmaceutical industry has partnered with governments, health providers, and civil society.

Industry contributes to the SDGs by exploring new ways to engage in multisectoral partnerships to improve access to innovation in LMICs.

These include:

In the 100 years since diabetes was discovered, the innovative pharmaceutical industry has helped pioneer new treatments, delivery mechanisms, and blood glucose monitoring devices.

These have reduced side effects and long-term complications and improved quality of life for people living with the condition.

More than 450 medicines are currently in development.

IFPMA and our member companies work with a range of stakeholders to ensure that people all over the world have access to the set of health products required for managing diabetes.

We collaborate with governments, civil society, heath providers, and private stakeholders to scale up successful existing initiatives and explore new collaborative models.

IFPMA is committed to the WHO Global Diabetes Compact, launched in April 2021.The Compact unites key players across all public and private sectors, including people living with diabetes, to shape a common agenda and drive action toward improved solutions for diabetes treatment and care in LMICs.

Among our member companies, 34 are taking part in 53 collaborations in diabetes. These focus on prevention, timely testing and diagnosis, access to medicines, and patient management and support.

The innovative pharmaceutical industry is constantly developing new ways of treating cardiovascular disease (CVD) related to the heart and circulation.

Over the years, scientists have discovered more about the interplay of various genetic, environmental, and lifestyle factors affecting CVD. This knowledge has allowed the innovative pharmaceutical industry to develop a range of effective treatments.

Despite this remarkable progress, CVD remains the leading cause of death worldwide, and hypertension is one of the major underlying risks.

In LMICs, IFPMA supports more integrated care and multipronged action plans to prevent, diagnose, manage, and care for CVD. This holistic model includes addressing related conditions such as hypertension and diabetes.

According to the WHO:

IFPMA and our innovative pharmaceutical company members actively took part in the Private Sector Dialogue on hypertension convened by the WHO in June 2022.

This dialogue was part of a series on NCDs that aims to support countries in health system strengthening and addressing issues of access to medicines, diagnostics, and care, especially in LMICs.